Short answer: no — not according to the evidence we currently have.
That is not the answer most of the internet gives you, and it is not the answer that sells creatine. But if you are on a GLP-1 receptor agonist and you are worried about losing muscle, you deserve to know what the research actually shows before you spend money on the wrong thing.
This article walks through what the data says, why the popular claim outstripped it, and what the evidence does support. If you want the practical side — dosing, hydration, kidney labs — that is in our companion piece, creatine while on a GLP-1.
The claim, and where it came from
The reasoning behind the popular version goes like this: GLP-1 medications cause significant lean mass loss; creatine is associated with lean mass gains in training studies; therefore creatine should offset the loss.
Each step sounds reasonable. The chain does not hold, for two separate reasons.
The premise is over-read. The widely repeated figure — that 25 to 40 percent of weight lost on a GLP-1 is lean mass — is a real measurement, not a marketing invention. What goes wrong is the next sentence, where “lean mass” gets restated as “muscle.” On a DXA scan it is not: lean mass includes organ tissue, connective tissue, glycogen, and body water, all counted together. The figure is an upper bound on muscle loss rather than a measurement of it, so reading it as the latter overstates what is happening to your skeletal muscle. (This number and every other key figure on this question live in our sourced statistics page.)
Langer and colleagues, writing in Cell Reports Medicine in 2026, pulled that compartment apart directly. In obese mice on tirzepatide, a meaningful share of what came off was liver tissue rather than skeletal muscle — and liver mass shrinking in a fatty liver is a good outcome, not a loss. That separation is preclinical: it took dissection, so it was done in animals. The paper’s human arm is a declared proof-of-concept — ten adults on semaglutide for twelve weeks, roughly 70 percent of weight lost from fat and 30 percent from lean body mass, without DXA — which again measures the whole lean compartment, not muscle on its own.
So: the scary number overstates muscle loss, the true share in humans has not been pinned down, and neither of those makes the loss zero. Still real, still worth addressing, but not the emergency the marketing describes.
The conclusion does not follow from the evidence. This is the more important gap. The lean-mass gains seen in creatine studies come from trials where participants were doing resistance training, usually while eating enough or in a surplus. Those are different conditions from a substantial calorie deficit driven by appetite suppression. You cannot assume a result transfers across that gap; you have to test it. And the test — DXA body composition data in people taking creatine while on a GLP-1, compared against people who are not — has largely not been run.
What the DXA evidence actually shows
When you look for a controlled trial showing that creatine, added on its own, reduces lean mass loss during GLP-1 therapy, you do not find one. A detailed review of the available evidence by Barbell Medicine goes through the relevant literature and reaches the same conclusion: the studies that exist do not support the claim being made in supplement marketing.
Two things are worth separating here.
First, absence of evidence is not evidence of absence. “No trial has shown this” is not “creatine definitely does nothing here” — a well-designed trial might yet find a small benefit. We are describing the state of the evidence, not making a claim about the biology.
Second, and this is the part that matters for your decision: the claim is unproven, and unproven is not good enough to build a strategy on. If a daily scoop of creatine is your muscle-protection plan on a GLP-1, you have chosen an intervention with no supporting body-composition data over interventions that have quite a lot of it.
There is a further measurement wrinkle. Creatine draws water into muscle cells, and DXA reads that intracellular water as lean mass, so a creatine user’s lean mass number can look better on a scan without any additional contractile tissue underneath it. Any future trial has to account for that.
What the evidence does support
The interventions with real backing for holding onto muscle during weight loss are not new, and not exciting.
Resistance training
Progressive resistance training is the single best-supported thing you can do to hold onto lean mass in a calorie deficit. This is not GLP-1-specific research; it is decades of consistent work across surgical weight loss, dieting, and aging populations. Lifting tells your body that the muscle is being used and is worth keeping.
The specifics matter less than the consistency. Two or three sessions a week covering the major movement patterns, with load that increases over time, does the work. For women over 40 it also has the broadest benefit beyond body composition — bone density, balance, and the ability to carry your own groceries at 75.
This question is being studied directly. NCT07457437 on ClinicalTrials.gov is a registered trial examining resistance training and lean mass preservation in people on GLP-1 receptor agonists. That trial exists because the mechanism is plausible and the supporting evidence is already strong enough to justify a dedicated study — a status creatine in this context has not reached.
Adequate protein
Protein intake is the other half. In a calorie deficit, protein needs go up rather than down, because your body is more likely to break down muscle tissue for amino acids when total intake is low. The general recommendation for someone losing weight and trying to hold muscle sits well above the standard 0.8 g/kg RDA — commonly 1.2 to 1.6 g/kg of body weight, and often higher in the sports nutrition literature.
GLP-1 medications make this genuinely difficult. Appetite suppression, early fullness, and slowed gastric emptying all conspire against eating a large volume of food, and protein-rich foods are often the ones that feel heaviest. Hitting a protein target on a GLP-1 usually requires deliberate planning rather than appetite-led eating.
This is also under active study. NCT07480109 on ClinicalTrials.gov is a registered trial examining elevated protein intake in middle-aged women on GLP-1 medications — the exact population and question this site exists for. Worth stating plainly, since we ask you to weigh this kind of thing elsewhere: that trial is sponsored by the National Pork Board, and the protein intervention under test is pork. A funder with a commercial stake in the result does not make a trial wrong, and registered trials are held to their pre-declared endpoints — but it is a conflict of interest you should know about before the results are reported, not after. Results are not in yet, and we will update this article when they are.
So where does creatine fit?
Creatine is not useless here. It is just doing a different job than the marketing suggests.
Creatine’s well-supported effect is on training performance: more available phosphocreatine means slightly more work per session — an extra rep, a bit more load, marginally faster recovery between sets. Over months of consistent lifting, more accumulated training volume tends to produce better strength and lean mass outcomes than less.
So the honest framing is: creatine improves the thing that protects your muscle, rather than protecting it directly. If you are training, it is a cheap, well-studied, low-risk addition that may make your training slightly more productive. If you are not training, you have bought a supplement whose main mechanism has nothing to act on.
That is a much smaller claim than “creatine protects your muscle on a GLP-1.” It is also one we can actually stand behind.
What we would change our mind on
Being clear about what would move us:
- A controlled trial with DXA body composition in people on a GLP-1, comparing creatine against placebo with resistance training and protein held constant across both arms, showing a difference in skeletal muscle.
- Enough trials of that design to rule out a single positive result being noise.
- A method for separating creatine’s intracellular water effect from actual contractile tissue, so the lean mass numbers mean what they appear to mean.
None of that exists today. If it appears, we will say so here — including if it contradicts what this article currently says.
The bottom line
Creatine does not stop muscle loss on a GLP-1, as far as the available evidence can tell us. What holds onto lean mass is resistance training and adequate protein, and both are being formally studied in this exact population. Creatine is a reasonable, inexpensive addition to a training programme, valued for what it does to your training rather than for a body-composition effect nobody has demonstrated.
If someone is selling you creatine primarily as muscle insurance for your GLP-1, they are ahead of the evidence. For how to use it sensibly alongside the things that do work, read creatine while on a GLP-1.